Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome

Maternal serum inhibin A levels are increased on average in pregnancies affected by Down syndrome (DS). However, some reports have found increased serum levels in women with pre‐eclamptic toxaemia as well. In the current study, maternal serum inhibin A was retrospectively measured in a series of 32 serum samples from pregnant women previously diagnosed as having either systemic lupus erythematosus (SLE) or primary antiphospholipid syndrome (APS). For comparison, normal medians were calculated from 57 unaffected control pregnancies together with a total of 854 samples tested at 13–19 weeks of gestation as part of the routine antenatal DS screening. All results were expressed in multiples of the gestation specific normal medians (MoM). A cubic regression formula was fitted, weighting for the number of women tested at each gestation. The median MoM value in the 16 cases of SLE and the 16 cases of primary APS is 0.60 (95% confidence interval 0.40–0.91) and 0.88 (95% confidence interval 0.66–1.17), respectively. For primary APS this was not statistically significant, whereas the SLE patients had a highly statistically significant reduction of serum inhibin A (p<0.002, Wilcoxon Rank sum Test, 2 tailed). Six pregnancies in the SLE group had a complicated obstetric outcome, i.e. missed abortion, placental abruption, exacerbation of the underlying disease which necessitated delivery, and severe postpartum haemorrhage. In 85% of this subgroup, serum inhibin A levels were below the normal 10th centile. The current data suggest that serum inhibin A is decreased on average in SLE patients. Those preliminary results might have various obstetric implications such as antenatal DS screening of SLE patients, identification of pregnant women at risk of developing SLE, who have presented for routine DS screening and for monitoring SLE patients throughout their pregnancy. Copyright © 2000 John Wiley & Sons, Ltd.

[1]  M. Frydman,et al.  Prenatal diagnosis of nail‐patella syndrome , 1999, Prenatal diagnosis.

[2]  U. Ekblad,et al.  Prediction of pre‐eclampsia with maternal mid‐trimester total renin, inhibin A, AFP and free β‐hCG levels , 1999, Prenatal diagnosis.

[3]  H. Cuckle,et al.  Maternal serum inhibin A can predict pre‐eclampsia , 1998, British journal of obstetrics and gynaecology.

[4]  K. Nicolaides,et al.  UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation , 1998, The Lancet.

[5]  J. Bar,et al.  Placental Isoferritin Levels in Pregnant Patients with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome , 1998, American journal of reproductive immunology.

[6]  E. Wallace,et al.  Maternal serum inhibin‐A in pregnancies complicated by insulin dependent diabetes mellitus , 1997, British journal of obstetrics and gynaecology.

[7]  N. Groome,et al.  Activin A and inhibin A as possible endocrine markers for pre-eclampsia , 1997, The Lancet.

[8]  H. Cuckle,et al.  COMBINING INHIBIN A WITH EXISTING SECOND‐TRIMESTER MARKERS IN MATERNAL SERUM SCREENING FOR DOWN'S SYNDROME , 1996, Prenatal diagnosis.

[9]  K. Spencer,et al.  SECOND‐TRIMESTER DIMERIC INHIBIN‐A IN DOWN'S SYNDROME SCREENING , 1996, Prenatal diagnosis.

[10]  H. Watt,et al.  MATERNAL SERUM INHIBIN‐A IN PREGNANCIES WITH INSULIN‐DEPENDENT DIABETES MELLITUS: IMPLICATIONS FOR SCREENING FOR DOWN'S SYNDROME , 1996, Prenatal diagnosis.

[11]  N. Wald,et al.  PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBIN‐A AS A SERUM MARKER , 1996, Prenatal diagnosis.

[12]  B. Walters,et al.  Elevated mid‐trimester hCG and maternal lupus anticoagulant , 1995, Prenatal diagnosis.

[13]  A. Tincani,et al.  Systemic lupus erythematosus and pregnancy: a prospective study. , 1992, Clinical and experimental rheumatology.

[14]  J. Kopelman,et al.  The Association of Antiphospholipid Antibodies With Pregnancies Complicated by Fetal Growth Restriction , 1991, Obstetrics and gynecology.

[15]  R. Derksen,et al.  Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[16]  M. D'Alton,et al.  Preeclampsia in diabetic pregnancies. , 1990, American journal of obstetrics and gynecology.

[17]  J. Scott,et al.  Obstetric complications associated with the lupus anticoagulant. , 1985, The New England journal of medicine.

[18]  L. Jovanovič,et al.  Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. , 1985, The New England journal of medicine.

[19]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[20]  H. Kronenberg,et al.  A Sensitive Test Demonstrating Lupus Anticoagulant and its Behavioural Patterns , 1978, British journal of haematology.